BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $62,671,981 | -14.7% | 920,699 | +2.2% | 2.42% | -5.4% |
| Q2 2023 | $73,508,468 | +11.7% | 900,508 | +1.5% | 2.55% | +10.2% |
| Q1 2023 | $65,793,695 | -8.4% | 886,827 | +2.3% | 2.32% | -17.6% |
| Q4 2022 | $71,823,808 | +32.2% | 866,600 | +353.1% | 2.81% | +31.2% |
| Q3 2022 | $54,314,000 | -19.0% | 191,246 | -1.2% | 2.14% | -14.7% |
| Q2 2022 | $67,068,000 | -19.7% | 193,480 | +0.4% | 2.51% | +2.1% |
| Q1 2022 | $83,478,000 | -15.0% | 192,773 | +1.6% | 2.46% | -2.3% |
| Q4 2021 | $98,181,000 | +6.1% | 189,781 | -0.6% | 2.52% | +1.4% |
| Q3 2021 | $92,523,000 | +8.0% | 190,938 | +0.4% | 2.48% | +3.6% |
| Q2 2021 | $85,632,000 | +19.5% | 190,183 | +1.4% | 2.40% | +10.7% |
| Q1 2021 | $71,649,000 | +20.7% | 187,597 | +0.4% | 2.17% | +22.1% |
| Q4 2020 | $59,344,000 | +27.3% | 186,880 | -0.7% | 1.77% | +3.6% |
| Q3 2020 | $46,621,000 | -6.8% | 188,191 | -0.7% | 1.71% | -6.9% |
| Q2 2020 | $50,035,000 | +43.0% | 189,475 | +2.7% | 1.84% | +8.1% |
| Q1 2020 | $34,986,000 | +49.4% | 184,506 | +73.0% | 1.70% | +73.3% |
| Q4 2019 | $23,414,000 | +13.6% | 106,665 | +1.3% | 0.98% | +7.7% |
| Q3 2019 | $20,603,000 | -6.3% | 105,295 | -0.2% | 0.91% | -3.1% |
| Q2 2019 | $21,995,000 | +5.6% | 105,498 | +0.6% | 0.94% | -2.6% |
| Q1 2019 | $20,827,000 | +42.4% | 104,895 | +3.8% | 0.97% | +23.7% |
| Q4 2018 | $14,626,000 | +229.4% | 101,065 | +364.6% | 0.78% | +302.6% |
| Q3 2018 | $4,440,000 | +38.7% | 21,753 | +0.5% | 0.19% | +17.6% |
| Q2 2018 | $3,202,000 | -1.6% | 21,643 | +0.5% | 0.16% | -10.8% |
| Q1 2018 | $3,254,000 | +125.3% | 21,543 | +93.3% | 0.18% | +112.6% |
| Q4 2017 | $1,444,000 | +24.4% | 11,143 | +16.0% | 0.09% | +19.2% |
| Q3 2017 | $1,161,000 | +4.0% | 9,603 | +1.1% | 0.07% | +1.4% |
| Q2 2017 | $1,116,000 | +18.2% | 9,500 | +2.3% | 0.07% | +7.5% |
| Q1 2017 | $944,000 | +8.5% | 9,285 | +9.7% | 0.07% | 0.0% |
| Q4 2016 | $870,000 | -1.0% | 8,465 | +5.5% | 0.07% | -1.5% |
| Q3 2016 | $879,000 | -0.9% | 8,025 | +2.0% | 0.07% | -6.8% |
| Q2 2016 | $887,000 | +24.2% | 7,865 | +4.1% | 0.07% | +17.7% |
| Q1 2016 | $714,000 | +55.9% | 7,555 | +48.6% | 0.06% | +51.2% |
| Q4 2015 | $458,000 | +21.5% | 5,085 | +24.8% | 0.04% | +5.1% |
| Q3 2015 | $377,000 | -8.3% | 4,075 | -2.4% | 0.04% | 0.0% |
| Q2 2015 | $411,000 | +16.1% | 4,175 | +18.4% | 0.04% | +11.4% |
| Q1 2015 | $354,000 | -8.3% | 3,525 | -15.6% | 0.04% | -16.7% |
| Q4 2014 | $386,000 | – | 4,175 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |